Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07501377

Effects of a 6-months Fiber- and Polyphenol-rich Diet on Brain Inflammatory Processes in Perimenopausal Women Living With Overweight or Obesity

People living with obesity have a higher risk of late-life cognitive decline and developing dementia. In women, the risk of cognitive decline may further raise during the menopausal transition, a period of substantial hormonal and metabolic changes.

Recent studies suggest that a healthy diet could help to prevent neurocognitive disorders by reducing inflammatory processes in the body and brain. Emerging evidence further indicates that the gut-brain axis and the intestinal microbiome play a crucial role in mediating this effect, through metabolic, immune, neuronal and vascular routes. Modifying the gut microbiota may thus counteract the heightened systemic inflammation seen in obesity and during menopausal transition to eventually benefit brain health.

Specifically, plant-based nutirents, such as fibre and polyphenols, have microbiome-changing, anti-inflammatory and neuroprotective properties that may slow brain aging and neuro-inflammation. However, evidence from human interventional studies and knowledge on the underlying mechanisms remain scarce.

This randomized controlled trial will therefore test whether altering gut bacteria through six months of daily intake of a personalized "polybiotic" dietary formula, compared to placebo, improves markers of brain health in women during the perimenopausal transition that are living with overweight or obesity. We plan to enroll 120 women aged 35-60 with overweight/obesity and elevated inflammatory blood markers, randomized to: intervention (7.5 or 15 g inulin, plus 200 mg resveratrol and 320 mg quercetin per day in powder form with main meals) or control (isocaloric maltodextrin). Exclusions include type 1 diabetes, current psychiatric/gastrointestinal disorders, and magentic resonance imaging (MRI) contraindications.

Before and after 26 weeks, participants will undergo brain MRI to assess inflammation-related brain markers, neuropsychological testing, anthropometric measurements, they will fill in a set of questionnaires and donate stool and blood. Gut bacteria will be profiled by next-generation sequencing; metabolites will be measured in blood and stool. The primary outcome is a proxy of neuroinflammation in the white matter assessed using diffusion-weighted MRI. Secondary analyses will examine blood-brain-barrier permeability and other functional and structural MRI measures, including MR spectoscropy. Mechanistic links among changes in inflammatory markers, microbiota composition, and short-chain fatty acids will be explored using path and network models.

This study may help to develop novel prevention and treatment strategies to mitigate obesity-related cognitive decline via the gut-brain axis.

Recruiting

Interested in participating?

Request Info

Key information

Age range

35 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Max Planck Institute for Human Cognitive and Brain Sciences

Leipzig, Saxony, 04103, Germany

Location status: Recruiting

Location contact

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • STRAW+10 -1 or -2
  • BMI > 25 or WHR >= 0.85
  • hsCRP > 1 mg/l
  • no MRI contra-indication
  • written informed consent

Exclusion criteria

  • occurrence of a clinically relevant psychiatric disease in the last 12 months (e.g., depression, substance abuse, eating disorder, schizophrenia)
  • type 1 diabetes
  • previous bariatric/gastric surgery
  • pregnancy or breastfeeding woman
  • severe untreated disease, cancer treatment last 12 months, any chronic gastric tract disease (IBS, Morbus Crohn, Heliobacter pylori Infection etc.) or any chronic inflammatory disease
  • Polycystic ovary syndrome, total ovarectomy
  • Intake of antibiotics in past 3 months, intake of inulin (>5g/day) or polyphenol supplementation (>50mg/day) in past 3 months

Treatment and study plan

Polybiotic dietary intervention

Dietary Supplement

7.5g or 15g of inulin + 200mg resveratrol + 320mg quercetin in a powder formula

Placebo

Dietary Supplement

Equicaloric maltodextrin in powder form

Primary outcomes

  1. Free water fraction averaged across the white matter skeleton

    Time frame: 6 months

    Free water (measured using multi-shell diffusion-weighted MRI at 3 Tesla) reflects extra-cellular water which can be considered an indicator of tissue edema and impaired blood brain barrier

Secondary outcomes

  1. Average grey matter kw from motion-compensated diffusion-weighted arterial spin labeling (ASL)

    Time frame: 6 months

    Water exchange rate over the blood-brain barrier will be measured using motion-compensated diffusion-weighted pseudo-continuous arterial-spin labeling (MCDW-ASL) or diffusion-prepared pCASL (DP-pCASL).

  2. Apparent diffusion coefficient of metabolites in the thalamus from diffusion-weighted MR spectoscropy

    Time frame: 6 months

    microglial activity will be quantified by measuring ADCCholine using diffusion-weighted magnetic resonance spectroscopy (dwMRS)

  3. Hypothalamic and hippocampal microstructure

    Time frame: 6 months

    microstructure will be assessed by mean diffusivity (MD)

  4. Episodic memory

    Time frame: 6 months

    California Verbal Learning Task

  5. Microbial Composition

    Time frame: 6 months

    Alpha/Beta diversity and abundance of specific bacteria (e.g. bifidobacteria) from microbiome shotgun sequencing

Other outcomes

  1. soma signal fraction in thalamus and hippocampus derived from multi-shell diffusion-weighted MRI

    Time frame: 6 months

    assessed using multi-shell diffusion-weighted MRI at 3T

  2. Pattern separation

    Time frame: 6 months

    Dprime and accuracy, reaction time of Mnemonic Similarity Task (MST)

  3. Executive function

    Time frame: 6 months

    Composite score of executive function tests derived from Trail Making Test, Attention Network Test, Stroop-Test

  4. pro-inflammatory marker high-sensitive C-reactive protein (hsCRP)

    Time frame: 6 months

    hsCRP measured in fasting blood

  5. waist-to-hip ratio, WHR

    Time frame: 6 months

    ratio of waist circumeference to hip circumference (measured)

  6. Adherence to healthy dietary pattern

    Time frame: 6 months

    A composite score based on self-reported information provided through diet protocol and food frequency questionnaire (FFQ)

  7. Menopausal symptoms

    Time frame: 6 months

    severity of menopausal symptoms based on a questionnaire

  8. Assessment of health data

    Time frame: 6 months (during 2 weeks at baseline, and follow-up, respectively)

    via wearables - smart devices finger ring and/or watch and glucose patch

  9. Demographics, anamnesis

    Time frame: 6 months

    Age, sex/gender, medical history, reproductive history, medication

  10. Total energy expenditure measured using a metabolic chamber

    Time frame: 6 months

    Oxygen consumption and CO2 production measured in a metabolic chamber, determining 24-hour total energy expenditure (TEE)

  11. body fat percentage

    Time frame: 6 months

    measured using bioelectrical impedance analysis (BIA)

  12. Gastrointestinal hormones

    Time frame: 6 months

    area under the curve (pre- to postprandial) of glukagon-like peptide 1 (GLP-1)

  13. Sex hormones

    Time frame: 6 months

    Follicle-stimulating hormon (FSH) measured in blood

Sponsors and collaborators

Lead sponsor

Max Planck Institute for Human Cognitive and Brain Sciences

Other

Registry information

Official study title

Effects of a Fiber- and Polyphenol-rich Diet on Brain Inflammatory Processes in Obesity

Acronym: INFLAME

Important dates

Study start
2026
Primary completion
2029
Study completion
2030
First posted
Mar 30, 2026
Registry last updated
Mar 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.